A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

Abstract Background Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with drug-drug interactions. Since both cardiovascular and renal disease,...

Full description

Bibliographic Details
Main Authors: Collins C. Iwuji, Duncan Churchill, Stephen Bremner, Nicky Perry, Ye To, Debbie Lambert, Chloe Bruce, Laura Waters, Chloe Orkin, Anna Maria Geretti
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Infectious Diseases
Subjects:
HIV
Antiretroviral drugs
Drug resistance
Protease inhibitor
B/F/TAF
Integrase inhibitor
Online Access:http://link.springer.com/article/10.1186/s12879-020-05240-y

Internet

http://link.springer.com/article/10.1186/s12879-020-05240-y

Similar Items